Today: 20 May 2026
Goldman Sachs stock slips on New Year’s Eve as Fed repo borrowing hits a record
31 December 2025
1 min read

Goldman Sachs stock slips on New Year’s Eve as Fed repo borrowing hits a record

NEW YORK, December 31, 2025, 14:39 ET — Regular session

  • Goldman Sachs shares down about 0.3% in afternoon trading
  • New York Fed repo backstop sees record year-end borrowing, highlighting demand for cash
  • Focus turns to Jan. 15 earnings and the Fed’s Jan. 27-28 policy meeting

Goldman Sachs shares slipped on Wednesday as U.S. stocks drifted lower in holiday-thin trading on the final session of 2025. The stock was down 0.3% at $881.64 after swinging between $876.75 and $886.26 earlier in the day.

The muted move still matters because year-end trading can exaggerate small flows. Portfolio rebalancing, tax positioning and balance-sheet constraints often make liquidity patchy, especially in big financial names.

Traders were also watching short-term funding markets, where banks and dealers typically hunt for cash at quarter- and year-end. Signs of strain can spill into bank shares by shifting funding costs and risk appetite.

In the broader market, Wall Street’s main indexes were modestly lower. At 1:47 p.m. ET, the Dow was down 0.19%, the S&P 500 was off 0.15% and the Nasdaq slipped 0.12%, though all three were still on track to finish the year with strong gains, Reuters reported.

Adding to the year-end focus, eligible firms borrowed a record $74.6 billion from the New York Fed’s Standing Repo Facility, Reuters reported. The “repo” market—short for repurchase agreements—is where firms raise short-term cash, often by borrowing against Treasuries; the Fed’s facility is designed to keep those rates from spiking. “It appears the funding market is more secure, there’s less panic, and more confidence that the SRF is working,” said Scott Skyrm of Curvature Securities. Reuters

Other large U.S. banks traded in a narrow range. JPMorgan shares were up about 0.2%, while Morgan Stanley was down about 0.4%.

Rates remained a key cross-current for the sector. The 10-year U.S. Treasury rate was around 4.14%, a benchmark that influences everything from bank funding costs to the appeal of dividend-paying financial stocks versus bonds.

Goldman’s shares are up about 57% so far in 2025, leaving investors more sensitive to any late-year profit-taking and positioning into January.

The Goldman Sachs Group is a global financial institution with businesses spanning investment banking, trading and asset and wealth management.

The next clear company catalyst is earnings. A Dec. 30 prospectus supplement said Goldman intends to file its quarterly earnings release for the quarter and year ended Dec. 31, 2025 on Form 8-K on or about Jan. 15, 2026.

After that, the market’s focus shifts quickly back to policy. The Fed’s next rate-setting meeting is scheduled for Jan. 27-28, and U.S. equity markets are closed on Jan. 1 for New Year’s Day before reopening on Jan. 2, according to official calendars.

For short-term traders, Wednesday’s intraday range set the near-term markers, with liquidity expected to improve once the holiday passes. Year-end price action often fades when full trading volumes return.

Stock Market Today

  • Parabilis Plans IPO to Fund Phase 3 Trial for Tumor Drug Following Regeneron Deal
    May 20, 2026, 5:56 AM EDT. Parabilis Medicines, a Massachusetts biotech, is preparing for an initial public offering (IPO) to finance the phase 3 trial of its tumor drug zolucatetide, targeting rare desmoid tumors. The drug, which inhibits the Wnt/β-catenin pathway implicated in many cancers, recently received FDA fast-track status. Proceeds will also support phase 1 trials for additional cancers. Parabilis secured a $50 million upfront payment and a $75 million equity investment from Regeneron in a deal to explore Parabilis' helicon peptide platform. The firm boasts over $300 million in cash from prior funding rounds. CEO Mathai Mammen aims to grow Parabilis into a fully integrated research, development, manufacturing, and commercialization company, relying on partnerships to finance its ambitions.

Latest articles

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

20 May 2026
OCI Energy and CPS Energy have begun building a 120-megawatt battery storage facility in southeastern Bexar County, aiming for commercial operation in 2027. The project follows a rise in average outage duration for CPS Energy customers to 75.38 minutes in 2025. OCI will own the facility, with CPS holding operational control. ING is financing construction, and LG Energy Solution Vertech is supplying batteries.
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

20 May 2026
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious
Previous Story

AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop